SLC39A6 may inhibit the ER in patients undergoing endocrine therapy, and also suggests that patients with ER + tumours expressing high levels of SLC39A6 may be candidate for a different type of endocrine treatment to further improve their outcome. Here, SLC39A6 is linked to neoplasm.